Información del artículo
RESUMEN
Objetivo
Revisar las indicaciones y las consideraciones de manejo perioperatorias de la terapia antiagregación plaquetaria (AAP).
MetodologíaCon las palabras clave "cirugía no cardiaca", "AAP" y "aspirina-clopidrogel" se hizo una búsqueda no sistemática en las bases de datos PubMed/Medline, SciElo.
ResultadosLa terapia de AAP se utiliza a menudo en el manejo de entidades médicas cardiovasculares y no cardiovasculares. Es importante asumir una posición clara con respecto a continuar, cambiar o suspender esta terapia en el contexto perioperatorio. Tal decisión debe fundamentarse en la valoración juiciosa del riesgo de sangrado y del riesgo de complicaciones perioperatorias secundarias a la suspensión del agente antiagregante que ha brindado al paciente condiciones adecuadas de manejo preoperatorias.
ConclusiónEn la mayoría de los escenarios de cirugía no cardiaca la suspensión de la aspirina en pacientes con enfermedad cardiovascular coronaria, cerebral o periférica debe evitarse si el riesgo de sangrado se considera leve o moderado.
Palabras clave::
Plaquetas
inhibidores de agregación plaquetaria
terapéutica
atención perioperativa. (Fuente: DeCS, BIREME).
Key words:
Blood platelets
platelet aggregation inhibitors
therapeutics
perioperative care. (Source: MeSH, NLM).
SUMMARY
Objective
To review the indications and perioperative management considerations for anti-platelet aggregation (APT) therapy.
MethodologyUsing "non-cardiac surgery", "APT" and "apirine-clopidogrel" as key words, a nonsystematic search was conducted in the PubMed/ Medline and SciELO databases.
ResultsAPT is used frequently for the management of cardiovascular and non-cardiovascular medical entities. It is important to adopt a clear stance regarding the continuation, change or withdrawal of this therapy in the perioperative context. That decision must be based on a judicious assessment of the risk of bleeding and the risk of perioperative complications secondary to the withdrawal of the antiplatelet agent that has offered the patient adequate management before surgery.
ConclusionIn most cases of non-cardiac surgery, withdrawal of aspirin in patients with coronary heart disease, cerebral or peripheral vascular disease must be avoided if the risk of bleeding is considered low or moderate.
El Texto completo está disponible en PDF
REFERENCES
[1.]
Antithrombotic Trialists' Collaboration.
Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients.
BMJ, 324 (2002), pp. 71-86
[2.]
D.L. Bhatt, K.A. Fox, W. Hacke.
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
N Engl J Med., 354 (2006), pp. 1706-1717
[3.]
M.S. Sabatine, C.P. Cannon, C.M. Gibson.
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
N Engl J Med., 352 (2005), pp. 1179-1189
[4.]
S. Yusuf, F. Zhao, S.R. Mehta.
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
N Engl J Med., 345 (2001), pp. 494-502
[5.]
S.J. Park, D.W. Park, Y.H. Kim.
Duration of dual antiplatelet therapy after implantation of drug-elut-ing stents.
N Engl J Med., 362 (2010), pp. 1374-1382
[6.]
E. Ferrari, M. Benhamou, P. Cerboni.
Coronary syndromes following aspirin withdrawal.
J Am Coll Cardiol., 45 (2005), pp. 456-459
[7.]
G.G.L. Biondi-Zoccai, M. Lotrionte, P. Agostoni.
A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50 279 patients at risk for coronary artery disease.
Eur Heart J., 27 (2006), pp. 2667-2674
[8.]
P. Albaladejo, C.M. Samama.
Patients under antiplatelet therapy.
Best Pract Res Clin Anaesthesiol., 24 (2010), pp. 41-50
[9.]
M.B. Leon, D.S. Baim, J.J. Popma.
A clínica! trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators..
N Engl J Med, 339 (1998), pp. 1665-1671
[10.]
C.L. Grines, R.O. Bonow, D.E. Casey.
Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents.
Circulation., 115 (2007), pp. 813-818
[11.]
J.A. Spertus, R. Kettelkamp, C. Vance.
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug eluting stent placement: results from the PREMIER registry.
Circulation., 113 (2006), pp. 2803-2809
[12.]
I. Iakovou, T. Schmidt, E. Bonizzoni.
Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.
JAMA., 293 (2005), pp. 2126-2130
[13.]
Mixed thoughts on how generic clopidogrel might impact patients, providers.
HeartWire [internet], (2006),
[14.]
A.A. Bavry, D.J. Kumbhani, T.J. Helton.
Late thrombosis of drug-eluting stents: A meta-analysis of randomized clinical trials.
Am J Med., 119 (2006), pp. 1056-1061
[15.]
J.P. Collet, G. Montalescot, B. Blanchet.
Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes.
Circulation., 110 (2004), pp. 2361-2367
[16.]
D.W. Park, S.W. Park, K.H. Park.
Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up.
Am J Cardiol., 98 (2006), pp. 352-356
[17.]
P. Albadalejo, T. Geeraerts, F. Francis.
Aspirin withdrawal and acute lower limb ischemia.
Anesth Analg., 99 (2004), pp. 440-443
[18.]
V.G. Nielsen, L.M. Asmis.
Hypercoagulability in the perioperative period.
Best Pract Res Clin Anaesthesiol., 24 (2010), pp. 133-144
[19.]
S. Goldman, J. Copeland, T. Moritz.
Improvement in early saphenous graft patency after coronary artery bypass surgery with antiplatelet therapy: Results of a veterans administration cooperative study.
Circulation., 77 (1988), pp. 1324-1332
[20.]
B. Lindblad, N.H. Persson, R. Takolander.
Does low-dose acetylsalicylic acid prevent trial.
Stroke., 24 (1993), pp. 1125-1128
[21.]
M. Torosian, E.L. Michelson, J. Morganroth.
Aspirin and Coumadin related bleeding after coronary artery bypass surgery.
Ann Intern Med., 89 (1978), pp. 325-328
[22.]
W. Burger, J.M. Chemnitius, G.D. Kneissl.
Lowdose aspirin for secondary cardiovascular risks after its perioperative withdrawal versus bleeding risks with it continuation - review and meta-analysis.
J Intern Med., 257 (2005), pp. 399-414
[23.]
M.K. Enver, I. Hoh, F.I. Chinegwundoh.
The management of aspirin in transurethral prostatectomy: current practice in the UK.
Ann R Coll Surg Engl., 88 (2006), pp. 280-283
[24.]
S.M. Mitchell, K.K. Sethia.
Hazards of aspirin withdrawal before transurethral prostatectomy.
BJU Int., 84 (1999), pp. 530
[25.]
E. Kargi, O. Babuccu, M. Hosnuter.
Complications of minor cutaneous surgery in patients under anticoagulant treatment.
Aesthetic Plast Surg., 26 (2002), pp. 483-485
[26.]
M.C. Korinth, J.M. Gilsbach, M.R. Weinzierl.
Low-dose aspirin before spinal surgery: results of a survey among neurosurgeons in Germany.
Eur Spine J., 16 (2007), pp. 365-372
[27.]
M. Whitson, A. Dikman, C. Von Althann.
Is gastroduodenal biopsy safe in patients receiving aspirin and clopidogrel?: a prospective, randomized study involving 630 biopsies.
J Clin Gastroenterol., 45 (2011), pp. 228-233
[28.]
P. Sierra, A. Gómez-Luque, J. Castillo.
Guía de práctica clínica sobre el manejo perioperatorio de antiagregantes plaquetarios en cirugía no cardiaca.
Rev Esp Anestesiol Reanim, 58 (2011), pp. 1-16
[29.]
W. Korte, M. Cattaneo, P.G. Chassot.
Peri-operative management of antiplatelet therapy in patients with coronary artery disease.
Thromb Haemost., 105 (2011), pp. 743-749
[30.]
G.L. Kaluza, J. Jospeh, J.R. Lee.
Catastrophic outcomes of noncardiac surgery soon after coronary stenting.
J Am Coll Cardiol., 35 (2000), pp. 1288-1294
[31.]
R. Ebrahimi, C. Dyke, R. Mehran.
Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery.
J Am Coll Cardiol., 53 (2009), pp. 1965-1972
[32.]
C.M. Samama, P. Bonnin, M. Bonneau.
Comparative arterial antithrombotic activity of clopidogrel and acetyl salicylic acid in the pig.
Thromb Haemost., 68 (1992), pp. 500-505
[33.]
A. Oscarsson, A. Gupta, M. Fredrikson.
To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial.
Br J Anaesth., 104 (2010), pp. 305-312
[34.]
W.F. Urmey, J.C. Rowlingson.
Do antiplatelet agents contribute to the development of perioperative spinal hematoma?.
Reg Anesth Pain Med., 23 (1998), pp. 146-151
[35.]
E. Vandermeulen.
Regional anaesthesia and anticoagulation.
Best Pract Res Clin Anaesthesiol., 24 (2011), pp. 121
[36.]
T.T. Horlocker, D.J. Wedel, H. Benzon, T.T. Horlocker, D.J. Wedel, H. Benzon.
Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation).
Reg Anesth Pain Med, 28 (2003), pp. 172-197
[37.]
C. Steve, P.J. Rosenfeld, S. Gayer.
Medical consequences of stopping anticoagulant therapy before intraocular surgery or intravitreal injections.
Retina., 27 (2007), pp. 813-815
[38.]
N. Narendran, T.H. Williamson.
The effects of aspirin and warfarin on haemorrhage in vitreoretinal surgery.
Acta Opthalmol Scand., 81 (2003), pp. 38-40
[39.]
M.C. Morice, P.W. Serruys, J.E. Sousa.
A randomized comparison of a sirolimuseluting stent with a standard stent for coronary revascularization.
N Engl J Med., 346 (2002), pp. 1773-1780
[40.]
J.W. Moses, M.B. Leon, J.J. Popma.
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.
N Engl J Med., 49 (2003), pp. 1315-1323
[41.]
G.W. Stone, S.G. Ellis, D.A. Cox.
A polymer-based paclitaxel-eluting stent in patients with coronary artery disease.
N Engl J Med., 350 (2004), pp. 221-231
[42.]
E.P. McFadden, E. Stabile, E. Regar.
Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy.
Lancet., 364 (2004), pp. 1519-1521
[43.]
A.T.L. Ong, E.P. McFadden, E. Regar.
Late angiographic stent thrombosis (LAST) events with drugeluting stents.
J Am Coll Cardiol., 45 (2005), pp. 2088-2092
[44.]
J. Daemen, P. Wenaweser, K. Tsuchida.
Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a larger two-institutional cohort study.
Lancet., 369 (2007), pp. 667-678
[45.]
J. Kotani, M. Awata, S. Nanto.
Incomplete neointimal coverage of sirolimuseluting stents: angioscopic findings.
J Am Coll Cardiol., 47 (2006), pp. 2108-2111
[46.]
P. Albadalejo, E. Marret, V. Piriou.
Perioperative management of antiplatelet agents in patients with coronary stents: recommendations of a French Task Force.
Br J Anaesth., 97 (2006), pp. 580-582
[47.]
L.A. Fleisher, J.A. Beckman, K.A. Brown.
ACC/ AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery.
Circulation., 116 (2007), pp. e418-e499
[48.]
R. Hall, C.D. Mazer.
Antiplatelet drugs: a review of their pharmacology and management in the perioperative period.
Anesth Analg., 112 (2011), pp. 292-318
[49.]
J.J. Lugo, E.F. Hurtado, L.I. Calderón.
Resistencia al ácido acetil salicílico y al clopidogrel: una entidad clínica emergente.
Revista Colombiana de Cardiología., 15 (2008), pp. 172-183
[50.]
STRATAGEM: Strategy for Managing Antiplatelet Therapy in the Perioperative Period of Non Coronary Surgery [internet], (2011),
Copyright © 2011. Revista Colombiana de Anestesiología
Opciones de artículo